Work

Supplementary Table 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 4: Clinical elimusertib response of coclinical PDXs.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4413905929
Cites:
Cited by:
Related to: 10